Newborn; Anemia, Pregnancy Anemia
Conditions
Brief summary
Erythroferrone (ERFE) is a recently identified iron-regulatory hormone that couples iron homeostasis to erythropoiesis but at this time there are no human data on this hormone in pregnant women and their neonates. The investigators hypothesize that ERFE is a sensitive biomarker of iron deficiency and anemia in pregnancy and neonates, and that it mediates the feedback mechanism to correct iron deficiency and anemia. To address this research gap, the investigators will measure ERFE in maternal serum, umbilical cord serum and placental tissue using an existing biospecimen archive.
Interventions
None listed
Sponsors
University of California, Los Angeles
Cornell University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
11 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy pregnant volunteers
Exclusion criteria
* Hemoglobinopathies * Pre-existing diabetes * Malabsorption diseases * Pregnancy induced hypertension * Elevated diastolic blood pressure (\>110) * Previous treatment for lead exposure or elevated childhood lead concentrations. * Preexisting medical conditions known to impact iron homeostasis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maternal Erythroferrone During Pregnancy | Measures will be obtained from maternal blood collected throughout the 40 weeks of pregnancy |
| Maternal Erythroferrone at Delivery | Measures will be obtained from maternal blood collected at delivery |
| Neonatal Erythroferrone at Birth | Measures will be obtained from umbilical cord blood collected at delivery |
| Placental Erythroferrone mRNA and Ferroportin protein Expression | Measures will be obtained from placental samples collected at delivery |
Countries
United States
Outcome results
None listed